These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
837 related articles for article (PubMed ID: 16421599)
21. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. Toda M; Martuza RL; Kojima H; Rabkin SD J Immunol; 1998 May; 160(9):4457-64. PubMed ID: 9574551 [TBL] [Abstract][Full Text] [Related]
22. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. Fu X; Nakamori M; Tao L; Amato R; Zhang X Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379 [TBL] [Abstract][Full Text] [Related]
23. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. Li H; Dutuor A; Fu X; Zhang X J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169 [TBL] [Abstract][Full Text] [Related]
24. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Prabhakar S; Messerli SM; Stemmer-Rachamimov AO; Liu TC; Rabkin S; Martuza R; Breakefield XO Cancer Gene Ther; 2007 May; 14(5):460-7. PubMed ID: 17304235 [TBL] [Abstract][Full Text] [Related]
26. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479 [TBL] [Abstract][Full Text] [Related]
27. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596 [TBL] [Abstract][Full Text] [Related]
28. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231 [TBL] [Abstract][Full Text] [Related]
29. Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction. Jeyaretna DS; Kuroda T Curr Opin Mol Ther; 2007 Oct; 9(5):447-66. PubMed ID: 17932809 [TBL] [Abstract][Full Text] [Related]
30. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888 [TBL] [Abstract][Full Text] [Related]
31. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer. Liu RB; Rabkin SD Chin Med J (Engl); 2005 Feb; 118(4):307-12. PubMed ID: 15740669 [TBL] [Abstract][Full Text] [Related]
32. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Li H; Dutuor A; Tao L; Fu X; Zhang X Clin Cancer Res; 2007 Jan; 13(1):316-22. PubMed ID: 17200370 [TBL] [Abstract][Full Text] [Related]
33. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10. Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473 [TBL] [Abstract][Full Text] [Related]
34. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Fu X; Tao L; Cai R; Prigge J; Zhang X Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513 [TBL] [Abstract][Full Text] [Related]
35. Herpes simplex virus-based vectors for the treatment of cancer and neurodegenerative disease. Latchman DS Curr Opin Mol Ther; 2005 Oct; 7(5):415-8. PubMed ID: 16248276 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452 [TBL] [Abstract][Full Text] [Related]
37. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus. Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584 [TBL] [Abstract][Full Text] [Related]
39. Oncolytic herpes simplex virus treatment of metastatic breast cancer. Wang J; Hu P; Zeng M; Rabkin SD; Liu R Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767 [TBL] [Abstract][Full Text] [Related]
40. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Todo T Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]